Quote:

---

When it was first announced I wondered if the agreement might cover future indications also, Even a split in Cytodyn's favor could mean more revenue for a BP then their own products produce.

---

I agree. There has to be some motivation beyond simply COVID distribution.

Frankly, even with an agreement that includes future indications, I would be surprised that a BP has that much interest in the logistics revenue associated with just moving vials around the country.

I could much more easily imagine that a BP would be interested in a commercialization agreement, and possibly for all future indications. That is a much larger and much more profitable undertaking. It also potentially offers a natural path for the relationship to advance to something more than an arm's length transaction.